Valeant rejected joint takeover bid from Takeda, TPG in spring: Reuters
Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP this spring that the Canadian specialty drug-maker rejected, a source told Reuters. Takeda and the U.S. private equity firm were ready to offer a substantial premium to Laval, Québec-based Valeant, whose stock had fallen about 65 percent this year up to the close of trade on April 22 as the drug-maker was not just seeking a new head but was also hit by an accounting scandal, the source added.
27 May 2016•2 mins read
